GlassScriptPhysician profile
David Keith Handshoe
NPI 1659371755
$9,770.70
in general payments reported to CMS, 2019-2025
45 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $1,249 · 2021: $1,165 · 2022: $1,928 · 2023: $1,884 · 2024: $1,361 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,775.09 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,346.01 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $972.84 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $776.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.86 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $478.33 | 2019-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $447.94 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $418.47 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $398.67 | 2020-2025 | Acthar |
| Grifols USA, LLC | $348.19 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Csl Behring | $338.33 | 2019-2025 | Hizentra |
| Axsome Therapeutics, INC. | $327.22 | 2023-2024 | Sunosi |
| United Therapeutics Corporation | $324.42 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $301.58 | 2020-2025 | Glassia, Hyqvia |
| Jazz Pharmaceuticals INC. | $294.47 | 2019-2025 | |
| Harmony Biosciences LLC | $289.90 | 2021-2025 | Wakix |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $252.16 | 2022 | |
| Mylan Specialty L.P. | $213.03 | 2020-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $170.78 | 2020-2024 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $153.90 | 2021-2023 | |
| Amgen INC. | $137.86 | 2021-2025 | Tezspire |
| Pfizer INC. | $137.50 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $130.46 | 2019-2020 | |
| Verona Pharma, INC. | $128.01 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $81.85 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $78.27 | 2024-2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $65.28 | 2021-2023 | |
| Philips North America LLC | $64.64 | 2022-2023 | |
| Pharming Healthcare, INC. | $64.01 | 2022-2023 | Ruconest |
| Baxter Healthcare | $60.80 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Avadel Cns Pharmaceuticals, LLC | $52.00 | 2024-2025 | Lumryz |
| Vapotherm INC | $43.16 | 2021-2022 | |
| Astellas Pharma US INC | $39.48 | 2020-2021 | |
| Shionogi INC | $34.72 | 2023 | Fetroja |
| Catalyst Pharmaceuticals, INC. | $34.31 | 2022 | |
| Resmed Corp | $31.30 | 2019-2022 | |
| Advanced Respiratory, INC | $30.53 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.36 | 2022 | |
| Nabriva Therapeutics, Plc | $18.64 | 2021 | |
| Hospira, INC. | $18.30 | 2023 | |
| Abbvie INC. | $18.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.25 | 2022 | |
| Mallinckrodt Enterprises LLC | $15.39 | 2019 | |
| Optinose US, INC. | $14.48 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
| Phadia US INC. | $13.57 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Handshoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.